Original Research

A case study of AstraZeneca’s omeprazole/esomeprazole chiral switch strategy

Published in: Volume 11 / Year 2022 / Issue 2
Author(s): ,
Page: 57-64

Author byline as per print journal: Federico J Piñeiro, Pharm, MPH; Fernández Argüelles Rogelio Alberto, Pharm, PhD Introduction/Objective: To describe the chiral switch, an evergreening strategy used by AstraZeneca to position… Read More »

On statistical evaluation for interchangeability of biosimilar products

Published in: Volume 11 / Year 2022 / Issue 2
Page: 51-6

Author byline as per print journal: Yuqi Li, BS Pharm; Shein-Chung Chow, PhD A biosimilar product is a biological product which is highly similar to an existing reference product in structure… Read More »

Extended stability of the trastuzumab biosimilar ABP 980 (KANJINTI™) in polyolefin bags and elastomeric devices

Published in: Volume 10 / Year 2021 / Issue 4
Page: 153-71

Author byline as per print journal: Lyndsay Davies1, PhD; Katie Milligan1, BSc; Mark Corris1, BSc; Ian Clarke1; Paul Dwyer1, MSc; Sarah Elizabeth Lee2, PhD; Jolene Teraoka3, BSc; Jill Crouse-Zeineddini3, PhD; Jane… Read More »

Reasons for patients’ generic drug switching at the pharmacy counter: a pilot study

Published in: Volume 10 / Year 2021 / Issue 3
Page: 119-22

Author byline as per print journal: Pieter J Glerum1,2, MSc; Mert Hayta1,3, PharmD, MSc; David M Burger4, PharmD, PhD; Cees Neef5, PharmD, PhD; Marcel L Bouvy3, PharmD, PhD; Marc Maliepaard1,6,… Read More »

Pharmacokinetics and bioequivalence of generic etoricoxib in healthy volunteers

Published in: Volume 10 / Year 2021 / Issue 3
Page: 113-8

Author byline as per print journal: Nishalini Harikrishnan1, BSc; Ka-Liong Tan2, DPhil; Kar Ming Yee3, BPharm; Alia Shaari Ahmad Shukri1, MSc; Nalla Ramana Reddy4, MBBS; Chuei Wuei Leong3, PhD Introduction/Study… Read More »

Variation in the prices of oncology medicines across Europe and the implications for the future

Published in: Volume 10 / Year 2021 / Issue 2
Page: 72-82

Author byline as per print journal: Brian Godman1,2,3, BSc, PhD; Steven Simoens4, MSc, PhD; Amanj Kurdi1,5, BSc, PhD; Gisbert Selke6; John Yfantopoulos7, PhD; Andrew Hill8, PhD; Jolanta Gulbinovič9, MD, PhD;… Read More »

Biosimilars in Saudi Arabia: a single-centre, open-label case series examining infliximab switching

Published in: Volume 10 / Year 2021 / Issue 2
Page: 68-71

Author byline as per print journal: Mansour Somaily1, MD; Hana Alahmari1, MD; Wejdan Abbag2; Shahenda Yousif4, MD; Nawar Tayfour4, MD; Nouf Almushayt2; Saleh Alhusayni3, MD; Saeed Almajadiah4, MD Background: A… Read More »

Summative usability evaluation of the YLB113 etanercept biosimilar autoinjector via simulation

Published in: Volume 10 / Year 2021 / Issue 2
Page: 61-7

Author byline as per print journal: Kelly Canham1, BSc Hons; Claire Newcomb2, MSc Introduction/Study Objectives: Etanercept is a tumour necrosis factor inhibitor indicated for the treatment of several inflammatory disorders.… Read More »

An assessment of trends in the Iranian pharmaceutical market following domestic production of selected medications (2007‒2017) and new considerations for health policymakers

Published in: Volume 10 / Year 2021 / Issue 1
Page: 33-43

Author byline as per print journal: Marzieh Zargaran1, PharmD, PhD Candidate; Abdol Majid Cheraghali 2,3, PharmD, PhD; Fatemeh Soleymani1,2, PharmD, MPH, PhD; Rajabali Daroudi4, BSc, MSc, PhD; Ali Akbari Sari4,… Read More »

Biosimilars – status in July 2020 in 16 countries

Published in: Volume 10 / Year 2021 / Issue 1
Page: 4-32, 41

Author byline as per print journal: Hye-Na Kang1, PhD; Robin Thorpe2, PhD; Ivana Knezevic1, PhD; Daehyun Baek3, PhD; Parichard Chirachanakul4; Hui Ming Chua5; Dina Dalili6, PhD; Freddie Foo7, MSc; Kai… Read More »

Page 1 of 6 1 2 3 4 5 Next »... 6
Go Back Print